Cleveland Clinic - Taussig Cancer Center

Taussig Cancer Institute

Cleveland, OH

Sorting 5 by

Not yet accepting

CARTITUDE-2

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • Phase 2
  • Myeloma Service
  • 21-009

Accepting patients

RedirecTT-1

A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • GPRC5D
  • Phase 1/2
  • Myeloma Service
  • 23-259

Accepting patients

Investigational Cord Blood Units

Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program (NCBP) for Unrelated Transplantation
Learn more
  • Allogeneic Stem Cell Transplant
  • Cord Blood
  • Phase 2
  • Transplant Service

Accepting patients

CaMMouflage

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Learn more
  • CAR T Cell (Allogeneic)
  • BCMA
  • Phase 1
  • Myeloma Service
  • 23-182

Accepting patients

GPC-100

A Phase 2, Randomized, Open-Label Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
Learn more
  • Randomization
  • Phase 2
  • Myeloma Service